Administration schedules of gemcitabine (G) and L19mTNF-α/melphalan (L-M) as single or combined treatments
| Schedules | WEHI-164 (day) | K7M2 (day) |
|---|---|---|
| (A) Therapeutic treatments | ||
| Tumor cell (s.c.) | 0 | 0 |
| G-G | +3/+10 | +12/+19 |
| L-M | +61/+7 | +151/+16 |
| G-L-M-G | +3/+6/+7/+10 | +12/+15/+16/+19 |
| L-M-G-G | +6/+7/+10/+17 | +15/+16/+19/+26 |
| (B) in vivo depletion protocol | ||
| Anti-CD4+ (i.p.) Anti-CD8+ (i.p.) | 0/+4/+8 | +9/+14/+19 |
The therapeutic schedules (A) and in vivo depletion protocols (B) reported were applied on both tumor models at the times indicated.
1
Day at which tumor volume is ~0.15 cm3.